A new observational report is drawing significant attention from the medical community and cancer patients alike. The study, submitted for peer review and available as a preprint on Zenodo, is the largest real-world analysis to date of cancer patients prescribed compounded ivermectin and mebendazole together, two antiparasitic drugs that have been studied independently for potential anti-cancer properties.

What the Report Found

The study enrolled 197 cancer patients who were prescribed compounded capsules containing 25 mg ivermectin and 250 mg mebendazole by licensed U.S. physicians through The Wellness Company. Of the 197 enrolled, 122 patients (61.9%) completed a 6-month follow-up. Among that group, the outcomes were striking:

• No current evidence of disease: 32.8% of patients
• Tumor regression (shrinkage): 15.6%
• Disease stabilization (no progression): 36.1%
• Disease progression: 15.6%
• Overall Clinical Benefit Ratio: 84.4%

The “clinical benefit ratio” combines patients who reported no evidence of disease, tumor regression, or stable disease. Put another way, nearly half of patients in the follow-up group (48.4%) reported that their cancer either disappeared or visibly shrank.

Who the Patients Were

Patients entered the study with a range of cancer types. The most represented were prostate cancer (27.9%), breast cancer (18.3%), lung cancer (8.6%), and colon cancer (5.1%), with additional malignancy types making up the remainder. At baseline, 37.1% reported actively progressing cancer, and many had prior treatment exposure: surgery (42.1%), chemotherapy (31.5%), and radiation (28.9%).

It is important to note that many patients were receiving concurrent treatments alongside the study protocol, including chemotherapy (27.9%), radiation (21.3%), dietary changes (37.7%), and supplements (49.2%). This multimodal context is relevant to interpreting the outcomes.

Safety and Tolerability

25.4% of patients reported side effects, predominantly mild gastrointestinal symptoms. Despite this, 93.6% of those who experienced side effects continued treatment. Overall protocol completion was 86.9%, and 66.4% were still on therapy at the 6-month mark.

The Research Team

The report was led by Nicolas Hulscher and co-authored by Kelly Victory, James Thorp, Drew Pinsky, and Alejandro Diaz-Villalobos, with involvement from Harvey Risch, Chairman of the President’s Cancer Panel. The work was conducted in collaboration with The Wellness Company’s Chief Medical Board and the McCullough Foundation.

Critical Context: What This Study Can and Cannot Tell Us

This is an observational, self-reported cohort study, not a randomized controlled trial. That distinction matters enormously in medicine. Research reviewers and independent fact-checkers have noted several important limitations:

• Patient outcomes were self-reported, with no independent verification of diagnoses or imaging results
• There was no control group, so it is impossible to know how patients would have fared without the drugs
• Many patients used concurrent conventional treatments, making it impossible to isolate the effect of ivermectin and mebendazole
• The researchers have financial ties to The Wellness Company, representing a conflict of interest
• The paper remains a preprint and has not yet completed peer review

The authors themselves acknowledge these limitations, describing the findings as “hypothesis-generating” and calling explicitly for “prospective, randomized, placebo-controlled trials to better understand safety, effectiveness, and optimal dosing.”

Why It Matters Despite the Limitations

Even with those caveats, observational data from real-world patients carries weight, particularly when the drugs in question are already well-studied, inexpensive, and have established safety profiles. Both ivermectin and mebendazole have been the subject of growing laboratory and clinical interest in oncology for years. Pre-existing research has demonstrated anti-proliferative and pro-apoptotic effects in various cancer cell lines.

The scale of this report, the first of its kind at 197 patients, gives researchers a real-world signal worth investigating further. The next step is the rigorous clinical trial this report calls for.

Anyone considering these treatments should speak with a licensed oncologist or physician. This report does not constitute medical advice, and ivermectin and mebendazole are not approved cancer treatments by the FDA.

Source: The Wellness Company | Full Preprint on Zenodo